Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H44N4O6 |
| Molecular Weight | 508.6508 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC(=N2)C(N)=O
InChI
InChIKey=HNJWVTLAOZFLEK-OOWZQQDUSA-N
InChI=1S/C26H44N4O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(31)35-18-20-22(32)23(33)26(36-20)30-19-28-25(29-30)24(27)34/h9-10,19-20,22-23,26,32-33H,2-8,11-18H2,1H3,(H2,27,34)/b10-9+/t20-,22-,23-,26-/m1/s1
Ribavirin elaidate (CP-4033; TRX-201), a Lipid Vector Technology derivative of ribavirin. It inhibits elongation factor F4E (elF4E), which stimulates cell growth. Translational Therapeutics Inc. received orphan drug status from the U.S. Food and Drug Administration (FDA) in 2011 for ribavirin elaidate in the treatment of aggressive follicular, medullary and anaplastic thyroid carcinoma.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
344011
Created by
admin on Sat Dec 16 02:03:08 UTC 2023 , Edited by admin on Sat Dec 16 02:03:08 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1352921-29-9
Created by
admin on Sat Dec 16 02:03:08 UTC 2023 , Edited by admin on Sat Dec 16 02:03:08 UTC 2023
|
PRIMARY | |||
|
DTXSID00159300
Created by
admin on Sat Dec 16 02:03:08 UTC 2023 , Edited by admin on Sat Dec 16 02:03:08 UTC 2023
|
PRIMARY | |||
|
4LU13X0I13
Created by
admin on Sat Dec 16 02:03:08 UTC 2023 , Edited by admin on Sat Dec 16 02:03:08 UTC 2023
|
PRIMARY | |||
|
49848291
Created by
admin on Sat Dec 16 02:03:08 UTC 2023 , Edited by admin on Sat Dec 16 02:03:08 UTC 2023
|
PRIMARY |
SUBSTANCE RECORD
